Water

Water

SCHEMBL3049600

NC(=O)[C@@H](N)Cc1c[nH]c2ccc(O)cc12.O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C known ✓ P28335 6/20 0.78
HTR1A known ✓ P08908 4/20 0.78
HTR2A known ✓ P28223 4/20 0.78
HTR2B known ✓ P41595 4/20 0.78
HTR7 known ✓ P34969 2/20 0.78
ADORA3 known ✓ P0DMS8 1/20 0.78
SLC6A4 known ✓ P31645 1/20 0.78
HTR1D known ✓ P28221 2/20 0.66
HTR1B known ✓ P28222 2/20 0.66
SCN9A known ✓ Q15858 2/20 0.59
HTR3E known ✓ A5X5Y0 1/20 0.55
HTR3B known ✓ O95264 1/20 0.55
HTR1E known ✓ P28566 1/20 0.55
HTR1F known ✓ P30939 1/20 0.55
DRD3 known ✓ P35462 1/20 0.55
HTR3A known ✓ P46098 1/20 0.55
HTR5A known ✓ P47898 1/20 0.55
HTR6 known ✓ P50406 1/20 0.55
HTR4 known ✓ Q13639 1/20 0.55
HTR3D known ✓ Q70Z44 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27717537 1.00 HTR2C (0.78) HTR2CNPSR1KDM4EHTR1AHTR2A
SCHEMBL5110752 0.99 HTR2C (0.80) HTR2CNPSR1KDM4EHTR1AHTR2A
SCHEMBL5066582 0.99 HTR2C (0.80) HTR2CNPSR1KDM4EHTR1AHTR2A
Hydrochloric Acid SCHEMBL5062770 0.97 HTR2C (0.78) HTR2CNPSR1KDM4EHTR1AHTR2A
Oxitriptan SCHEMBL10703675 0.93 NPSR1 (0.90) HTR2CNPSR1KDM4EHTR1AHTR2A
Oxitriptan SCHEMBL29189810 0.89 NPSR1 (0.97) HTR2CNPSR1KDM4EHTR1AHTR2A
Oxitriptan SCHEMBL29189812 0.89 NPSR1 (0.97) HTR2CNPSR1KDM4EHTR1AHTR2A
Oxitriptan SCHEMBL29189796 0.89 NPSR1 (0.97) HTR2CNPSR1KDM4EHTR1AHTR2A
Oxitriptan SCHEMBL29189800 0.89 NPSR1 (0.97) HTR2CNPSR1KDM4EHTR1AHTR2A
Oxitriptan SCHEMBL43242 0.87 NPSR1 (1.00) HTR2CNPSR1KDM4EHTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2983473-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS Mountain Llc (US) 2016-02-17 EP claimed
US-20140350064-A1 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS MOUNTAIN LLC 2014-11-27 US claimed
WO-2014144130-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS MOUNTAIN LLC (US) 2014-09-18 WO claimed
US-20120183600-A1 NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS CHEN CHIEN-HUNG (US) 2012-07-19 US claimed
EP-1789052-A4 COMPOSITION AND METHOD FOR INDUCING OR RESTORING LOCOMOTOR FUNCTIONS IN AN ANIMAL UNIV LAVAL (CA) 2008-05-21 EP claimed
US-20080096847-A1 Composition And Method For Inducing Or Restoring Locomotor Functions In An Animal UNIVERSITE LAVAL 2008-04-24 US claimed
EP-1789052-A1 COMPOSITION AND METHOD FOR INDUCING OR RESTORING LOCOMOTOR FUNCTIONS IN AN ANIMAL Université Laval (CA) 2007-05-30 EP claimed
WO-2006026850-A1 COMPOSITION AND METHOD FOR INDUCING OR RESTORING LOCOMOTOR FUNCTIONS IN AN ANIMAL UNIVERSITE LAVAL (CA) 2006-03-16 WO claimed
US-20030187055-A1 Synergistic pharmaceutical combinations for treating obesity BANK OF AMERICA, N.A., AS AGENT 2003-10-02 US claimed
US-20030162725-A1 Synergistic pharmaceutical combinations for treating obesity with EGCG BANK OF AMERICA, N.A., AS AGENT 2003-08-28 US claimed
US-6579899-B1 Precursor or prodrug of serotonin, tryptophan or 5-hydroxytryptophan MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2003-06-17 US claimed
WO-2002038141-A9 COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT MASSACHUSETTS INST TECHNOLOGY (US) 2003-02-13 WO claimed
US-20020173549-A1 Compositions and methods for treatment of mild cognitive impairment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-11-21 US claimed
EP-1253915-A1 METHOD FOR TREATING STRESS WITH A PRECURSOR OF SEROTONIN Massachusetts Institute of Technology (US) 2002-11-06 EP claimed
WO-2002038141-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2002-05-16 WO claimed
WO-2001054681-A2 COMPOSITION FOR TREATMENT OF STRESS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-08-02 WO claimed
US-9315483-B2 Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS, INC. (US) 2016-04-19 US disclosed
EP-2983473-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS Mountain Llc (US) 2016-02-17 EP disclosed
WO-2001067890-A2 COMPOSITION AND METHOD TO TREAT WEIGHT GAIN AND OBESITY ATTRIBUTABLE TO PSYCHOTROPIC DRUGS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-09-20 WO disclosed
WO-2001054681-A2 COMPOSITION FOR TREATMENT OF STRESS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-08-02 WO disclosed